Innova Biosciences and Mologic Sign Supply and Licensing Agreement


Mark Davis CEO of Mologic is pleased to announce that Mologic has signed a supply and licensing agreement with Innova Biosciences, a specialist provider of bioconjugation products and services to incorporate Innova’s Lightning-Link and InnovaCoat GOLD technologies as part of Mologic’s commercial assay development services and range of immunoassays.

The deal provides Mologic with rights to incorporate Innova Technology into its products, including its full point of care diagnostic portfolio in addition to its B.I.T.S.™ range of high quality laboratory diagnostic assays.  The agreement also allows Mologic to provide its customers direct access to Innova’s leading technology when incorporated into product development programmes.

Lightning-Link is the fastest, easiest to use, most efficient antibody conjugation method available. Requiring only 30 seconds hands-on time, with no separation steps and 100% antibody recovery, Lightning-Link provides highly stable conjugates due to its covalent bonding mechanism.

InnovaCoat GOLD is a one-step kit for conjugation of antibodies, proteins and peptides or any other biomolecule with an amine group, using gold nanoparticles. The superior quality gold nanoparticles have a proprietary surface coating, which enhances colloidal stability and enables covalent linking of the nanoparticle to an antibody.

Dr Nick Gee, CEO of Innova Biosciences, commented: “We are delighted to sign this agreement with Mologic, which forms part of our strategy of working with high-quality partners. The Company has an excellent reputation in immunoassay development, and we see their decision to work with Lightning-Link and InnovaCoat GOLD as a powerful endorsement of our technologies.”

Mark Davis, CEO of Mologic, said: “We have already benefitted from using Innova’s conjugation technology and have seen excellent results across the product range.  The simplicity of Lightning-Link kits has led to them becoming essential tools for our highly efficient research group. Extending the relationship to a formal supply and licensing agreement will enable us to continue using the technologies in assay development, and as part of our custom services and disruptive product pipeline. We look forward to working with Innova further.”

Innova’s bioconjugation technologies have a wide range of applications across biological research, and in the development and manufacturing of diagnostic kits. The expanding portfolio is supplied to research laboratories, pharmaceutical companies, biotechnology companies and diagnostic companies worldwide.

Click here to see the agreement on Innova’s Web site.